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Abstract: Systemic lupus erythematosus (SLE) is characterized with aberrant responses in the
immune systems and lupus nephritis (LN) is one of the most serious complications of SLE. This study
evaluated the clinical significance of different nutritional indices in 207 renal biopsy-proven LN
patients. The clinical and laboratory data were reviewed, and five different nutritional indices were
calculated: (i) Controlling nutritional status (CONUT) score; (ii) prognostic nutritional index (PNI);
(iii) nutritional risk index; (iv) neutrophil-to-lymphocyte ratio; and (v) body mass index. The factors
associated with end-stage renal failure (ESRF) were assessed using a Cox-proportional hazard analysis.
The patients with ESRF had significantly lower median PNI (31.1 vs. 34.7, p = 0.012) than those
without ESRF at baseline. The CONUT score and PNI had the highest correlation between the SLE
disease activity index-2000 (r = 0.467 and p = −0.356, all p < 0.001) and was significantly associated
with SLE activity-related measures. In the Cox-proportional hazard analysis, PNI (odds ratio 0.925,
95% confidence interval 0.865–0.989, p = 0.022) was independently associated with ESRF along with
creatinine and chronicity index, and the renal survival rate was significantly lower in patients with
PNI ≤35.41 than in those with PNI >35.41 (p = 0.003). Among nutritional indices, the CONUT score
and PNI better correlated with disease activity and PNI was associated with ESRF.
Keywords: lupus nephritis; end-stage renal failure; nutrition; index; prognosis
1. Introduction
Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease, with a characteristic
feature of aberrant responses in the innate and adaptive immune system [1]. These abnormalities in
the immune system contribute to the development of autoimmunity in SLE, damaging various organs.
Regarding the organs involved in SLE, lupus nephritis (LN) is one of the most serious complications
which is associated with a high morbidity and mortality [2]. It is estimated that, during the course of
SLE, nearly 60% of patients develop LN, among whom 10% eventually develop end-stage renal failure
(ESRF) [3,4]. Therefore, it is important to identify patients highly susceptible to ESRF. The ultimate goal
in treating LN is to prevent ESRF through appropriate immunosuppressive treatment. Accordingly,
numerous efforts have been made to discover the factors associated with patient prognosis in LN.
In general, malnutrition is considered to be a condition associated with increased morbidity and
mortality [5]. Meanwhile, compromised nutritional status was reported to be associated with chronic
inflammation as well as the development of autoimmunity [6]. Therefore, investigations have been
made to elucidate the prognostic implication of the nutritional status in various diseases. Interestingly,
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some studies have indicated that abnormalities in the nutritional status are associated with a poor
prognosis in malignancies, as well as autoimmune diseases, such as rheumatoid arthritis (RA) and
systemic sclerosis. This suggests that assessment of malnutrition could provide clinically valuable
information regarding patient prognosis [7–9].
Traditionally, anthropometric measures, such as the height or body mass index (BMI) or laboratory
tests, i.e., albumin, prealbumin, and total cholesterol level in the blood, have been used to assess the
individual’s nutritional status [10,11]. Nonetheless, because there is no common consensus regarding
the most useful tool to assess the nutritional status, inconsistencies abound regarding the prognostic
implication of nutritional status in various diseases. Recently, mini-nutritional indices including
the controlling nutritional status (CONUT) score, prognostic nutritional index (PNI), nutritional risk
index (NRI), and neutrophil-to-lymphocyte ratio (NLR) have also been increasingly used as surrogate
markers to reflect the patients’ nutritional status [12–14]. Given that SLE is a representative systemic
inflammatory autoimmune disease, it could be speculated that nutritional indices at diagnosis could
be associated with patient prognosis in SLE. However, the predictive potential of nutritional indices
for the prognosis of LN is still unknown. Hence, the aim of this study was to (i) investigate the
association between 5 different nutritional indices with disease activity, and (ii) evaluate whether these
nutritional indices are associated with the development of ESRF in patients with biopsy-proven LN
during the follow-up.
2. Materials and Methods
2.1. Patient Inclusion
The medical records of 260 patients who had undergone renal biopsy between August 2005 and
August 2018 and were diagnosed with LN were reviewed. From the 260 patients included, this study
excluded 53 for the following reasons: (i) Patients who did not fulfil the 1997 revised American College
of Rheumatology (ACR) classification criteria for SLE [15,16]; (ii) patients with histopathologic findings
incompatible to the criteria proposed by the 2003 International Society of Nephrology/Renal Pathology
Society (ISN/RPS) [17,18]; (iii) in LN patients who had undergone repeat renal biopsy, only the result
of the first biopsy was used. Finally, a total of 207 patients were included. This study was approved by
the Institutional Review Board of Severance Hospital and conducted in accordance with the principles
set forth in the Declaration of Helsinki, and the requirement to obtain informed consent was waived
because of the retrospective study design (4-2018-1083).
2.2. Clinical and Laboratory Data Collection
The authors obtained the clinical and laboratory data of the date when the pathologic diagnosis
of LN was made. The demographic data collected included age and sex. For SLE activity-related
measures, the following were evaluated: The SLE disease activity index-2000 (SLEDAI-2K); white
blood cell (WBC) and platelet counts; the levels of complement (C)3, C4, and anti-dsDNA; and the
urinary protein/creatinine ratio (P/Cr), which is a laboratory component of SLEDAI-2K [19]. The clinical
features of patients consisted of skin rashes, photosensitivity, oral ulcers, arthritis, serositis, neurologic,
hematologic, and immunologic disorders, according to the 1997 ACR classification criteria [15]. Other
laboratory data included lymphocyte count, erythrocyte sedimentation rate (ESR), and levels of
C-reactive protein (CRP), creatinine, total cholesterol, serum albumin, aspartate aminotransferase
(AST), and alanine aminotransferase (ALT). The glomerular filtration rate (GFR) was calculated by the
chronic kidney disease epidemiology collaboration study equation [20]. Concerning renal biopsy data,
the class of LN as well as the activity and chronicity indices were assessed based on the 2003 ISN/RPS
classification criteria. The medication usage after the diagnosis of LN was assessed using the Korean
drug utilization system.
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2.3. Nutritional Indices Selection and Calculation
Five different measures of nutritional indices were included in the study: CONUT score, PNI, NRI,
NLR, and BMI. The calculations of CONUT score, PNI, NRI, NLR, and BMI were performed according
to the following formulae: (i) CONUT score is the sum of serum albumin score, total lymphocyte count
score, and total cholesterol score based on a predefined cut-off (Supplementary Table S1) [21]; (ii) PNI is
10 × serum albumin value (g/dL) + 0.005 × total lymphocyte count in the peripheral blood (/mm3) [22];
(iii) NRI is (1.519 × serum albumin (g/dL)) + (41.7 × weight (kg)/ideal body weight (kg)) [13]; (iv) NLR
is the total neutrophil count in the peripheral blood/total lymphocyte count in the peripheral blood
(/mm3) [23]; (v) BMI is weight (kg)/height (m2). Being overweight was defined as a BMI of over 23.0,
in accordance with the Asia-Pacific guidelines of obesity classification [24].
2.4. Statistical Analysis
All statistical analyses were performed using MedCalc statistical software version 18.11 (MedCalc
Software, Ostend, Belgium). The continuous variables were presented as median and interquartile
ranges, and categorical variables were presented as frequencies and percentages. For the comparison
of continuous and categorical variables, the Mann-Whitney U test and Kruskal-Wallis test, and the
chi-square or Fisher’s exact test were used as appropriate. The correlation between nutritional indices
and variables were assessed using the Pearson’s correlation analysis. Low and high PNI was defined
using receiver operating characteristics (ROC) curve and patients with PNI ≤35.41 were classified as
having low PNI, while patients with PNI >35.41 were classified as having high PNI. Kaplan-Meier
analysis was used to compare the renal survival rate of patients with low and high PNI. Univariable
and multivariable Cox-proportional hazard analysis was used to evaluate factors associated with ESRF.
In all statistical analysis, a two-tailed p < 0.05 was considered to be significant.
3. Results
3.1. Clinical Characteristics of Patients
The baseline characteristics of patients included in the study are described in Table 1. The median
age was 36.0 years and 186 (89.9%) of the patients were female. The median follow-up duration was
57.1 months. When the patients were divided into those with and without ESRF during the follow-up,
20 (9.7%) were classified as having ESRF, while 187 (90.3%) were classified as without. Regarding
SLE activity-related measures, the patients with ESRF had significantly lower platelet counts and
anti-dsDNA titres. There was no significant difference in the clinical features between the groups.
In addition, the patients with ESRF presented with lower lymphocyte counts and GFR but higher
creatinine levels at diagnosis. For renal biopsy data, mixed class V LN was observed more frequently
in patients without ESRF, whereas the chronicity index was significantly higher in patients with ESRF.
In addition, when the authors compared the nutritional indices between the groups, differences were
found only in PNI, and patients with ESRF had significantly lower PNI than those without (median
PNI 31.1 vs. 34.7, p = 0.012). No significant differences were noted regarding the medications that were
administered in both groups during the follow up (Supplementary Table S2).
Table 1. The baseline characteristics of patients at lupus nephritis diagnosis.
Variables Total(n = 207)
Patients with ESRF
(n = 20)
Patients without ESRF
(n = 187) p-value
Demographic data
Age, years 36.0 (27.0–46.0) 37.5 (32.5–51.0) 36.0 (26.0–46.0) 0.210
Female sex, n (%) 186 (89.9) 19 (95.0) 167 (89.3) 0.700
Follow-up duration, months 57.1 (17.5–90.8) 33.3 (9.9–82.9) 59.2 (19.7–93.6) 0.214
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Table 1. Cont.
Variables Total(n = 207)
Patients with ESRF
(n = 20)
Patients without ESRF
(n = 187) p-value
SLE activity-related
measures
SLEDAI-2K 9.0 (7.0–12.0) 9.0 (5.0–11.0) 9.0 (7.0–13.0) 0.079
WBC count (/mm3) 4560.0 (3337.5–6805.0) 4390.0 (2795.0–7755.0) 4560.0 (3372.5–6650.0) 0.767
Platelet count (×1000/mm3) 205.0 (138.3–251.8) 183.5 (68.5–222.0) 207.0 (145.8–254.0) 0.036
Complement 3, mg/dL 45.6 (29.5–69.1) 42.1 (27.5–59.5) 45.9 (29.6–70.8) 0.374
Complement 4, mg/dL 6.2 (3.2–13.3) 6.8 (3.8–12.7) 6.2 (3.1–13.3) 0.995
Anti-dsDNA (IU/mL) 174.8 (10.3–379.0) 25.0 (0.0–245.2) 196.9 (20.3–379.0) 0.042
Urinary P/Cr ratio 2.9 (1.5–6.1) 4.2 (1.5–6.9) 2.8 (1.5–5.9) 0.422
Clinical features, n (%)
Skin rash 55 (26.6) 4 (20.0) 51 (27.3) 0.601
Photosensitivity 14 (6.8) 0 (0.0) 14 (7.5) 0.370
Oral ulcer 22 (10.6) 1 (5.0) 21 (11.2) 0.702
Arthritis 11 (5.3) 0 (0.0) 11 (5.9) 0.605
Serositis 48 (23.2) 6 (30.0) 42 (22.5) 0.449
Neurologic disorder 2 (1.0) 0 (0.0) 2 (1.1) 0.999
Hematologic disorder 179 (86.5) 18 (90.0) 161 (86.1) 0.999
Immunologic disorder 183 (88.4) 17 (85.0) 166 (88.8) 0.710
Laboratory data
Lymphocyte count (/mm3) 900.0 (602.5–1260.0) 655.0 (330.0–1070.0) 940.0 (610.0–1270.0) 0.012
ESR (mm/h) 48.0 (26.0–75.0) 46.0 (28.0–66.5) 48.0 (26.0–75.0) 0.867
CRP (mg/L) 2.3 (1.0–7.3) 4.7 (1.7–15.8) 2.3 (1.0–6.3) 0.061
Cr (mg/dL) 0.8 (0.6–1.1) 1.6 (0.9–3.6) 0.8 (0.6–1.1) <0.001
GFR (CKD-EPI),
mL/min/1.73 m2 94.0 (64.3–115.0) 38.5 (17.0–73.5) 100.0 (69.0–117.0) <0.001
Total cholesterol (mg/dL) 196.0 (159.3–243.8) 220.0 (185.0–234.5) 195.0 (156.0–245.8) 0.557
Serum albumin (g/dL) 2.9 (2.3–3.4) 2.5 (2.1–3.1) 2.9 (2.3–3.4) 0.067
AST (IU/L) 21.0 (17.0–35.5) 26.0 (16.5–44.5) 21.0 (17.0–34.0) 0.366
ALT (IU/L) 16.0 (10.0–25.0) 15.0 (9.5–30.0) 16.0 (10.0–25.0) 0.684
Renal biopsy data
Lupus nephritis class, n (%)
Class I 3 (1.4) 0 (0.0) 3 (1.6) 0.999
Class II 8 (3.9) 0 (0.0) 8 (4.3) 0.999
Pure class III 49 (23.7) 5 (25.0) 44 (23.5) 0.883
Pure class IV 92 (44.4) 13 (65.0) 79 (42.2) 0.052
Pure class V 23 (11.1) 1 (5.0) 22 (11.8) 0.706
Mixed class V 31 (105.0) 0 (0.0) 31 (16.6) 0.049
Class V + II 1 (0.5) 0 (0.0) 1 (0.5)
Class V + III 21 (10.1) 0 (0.0) 21 (11.2)
Class V + IV 9 (4.3) 0 (0.0) 9 (4.8)
Class VI 1 (0.5) 1 (5.0) 0 (0.0) 0.097
Activity/Chronicity index
Activity index 7.0 (2.0–11.0) 8.5 (4.5–12.0) 7.0 (2.0–11.0) 0.126
Chronicity index 1.0 (1.0–2.0) 2.0 (1.5–5.0) 1.0 (1.0–2.0) <0.001
Nutritional indices
CONUT score 4.0 (3.0–5.0) 4.5 (4.0–5.5) 4.0 (3.0–5.0) 0.173
PNI 33.9 (26.7–39.3) 31.1 (23.7–34.1) 34.7 (27.0–39.9) 0.012
NRI 48.8 (44.4–53.2) 49.8 (44.5–53.8) 48.7 (44.4–53.0) 0.584
NLR 3.7 (2.1–6.7) 4.7 (2.4–12.4) 3.6 (2.1–6.3) 0.070
BMI 21.9 (20.0–24.0) 22.4 (20.1–25.1) 21.8 (19.9–23.9) 0.595
The values are expressed as the median (interquartile range) or n (%). ESRF, End-stage renal failure; SLE,
Systemic lupus erythematosus; SLEDAI-2K, Systemic lupus erythematosus disease activity index-2000; WBC,
White blood cell; P/Cr, Protein/creatinine; ESR, Erythrocyte sedimentation rate; CRP, C-reactive protein; Cr,
Creatinine; GFR, Glomerular filtration rate; CKD-EPI, Chronic kidney disease epidemiology collaboration; AST,
Aspartate aminotransferase; ALT, Alanine aminotransferase; CONUT, Controlling nutritional status; PNI, Prognostic
nutritional index; NRI, Nutritional risk index; NLR, Neutrophil to lymphocyte ratio; BMI, Body mass index.
3.2. Correlation between Variables and Nutritional Indices
When the association between variables and nutritional indices were evaluated, SLE disease
activity-related measures, such as SLEDAI-2K, WBC and platelet count, C3, C4, and anti-dsDNA levels,
and urinary P/Cr ratio, were significantly correlated with the CONUT score and PNI. SLEDAI-2K had
the highest correlation with CONUT score, followed by PNI (r = 0.467, and r = −0.356, all p < 0.001).
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Although SLEDAI-2K and C3 were correlated with NRI, the association was weak. Moreover, significant
correlations between the WBC count and the NLR were found, and urinary P/Cr ratio was associated
with BMI among SLE activity-related measures (Table 2).
Table 2. Correlation analysis between variables and nutritional indices at lupus nephritis diagnosis
Variables CONUT Score PNI NRI NLR BMI
SLE activity-related measures
SLEDAI-2K 0.467 (<0.001) −0.356 (<0.001) −0.183 (0.008) −0.091 (0.192) −0.088 (0.206)
WBC count (/mm3) −0.264 (<0.001) 0.205 (0.003) 0.053 (0.449) 0.548 (<0.001) 0.089 (0.200)
Platelet count
(×1000/mm3) −0.329 (<0.001) 0.260 (<0.001) 0.063 (0.371) 0.072 (0.302) −0.002 (0.978)
Complement 3, mg/dL −0.502 (<0.001) 0.377 (<0.001) 0.138 (0.047) 0.058 (0.403) 0.086 (0.217)
Complement 4, mg/dL −0.335 (<0.001) 0.223 (0.001) 0.083 (0.236) 0.052 (0.454) 0.024 (0.737)
Anti-dsDNA (IU/mL) 0.278 (<0.001) −0.144 (0.038) −0.046 (0.508) −0.089 (0.201) 0.007 (0.919)
Urinary P/Cr ratio 0.221 (0.001) −0.515 (<0.001) 0.031 (0.655) 0.064 (0.361) 0.151 (0.030)
Laboratory data
Lymphocyte count (/mm3) −0.662 (<0.001) 0.549 (<0.001) 0.102 (0.145) −0.400 (<0.001) 0.057 (0.413)
ESR (mm/hr) 0.101 (0.148) −0.105 (0.134) −0.095 (0.173) −0.109 (0.119) −0.090 (0.198)
CRP (mg/L) 0.246 (<0.001) −0.141 (0.043) 0.059 (0.401) 0.166 (0.017) 0.137 (0.049)
Cr (mg/dL) 0.109 (0.118) −0.153 (0.028) 0.021 (0.762) 0.097 (0.166) 0.100 (0.153)
GFR (CKD-EPI),
mL/min/1.73 m2 −0.042 (0.550) 0.118 (0.090) −0.130 (0.062) −0.084 (0.228) −0.216 (0.002)
Total cholesterol
(mg/dL) −0.133 (0.056) −0.274 (<0.001) 0.091 (0.192) 0.144 (0.038) 0.165 (0.018)
Serum albumin (g/dL) −0.611 (<0.001) 0.922 (<0.001) 0.147 (0.034) −0.135 (0.053) −0.055 (0.433)
AST (IU/L) 0.191 (0.006) −0.097 (0.164) −0.091 (0.190) 0.010 (0.887) −0.111 (0.110)
ALT (IU/L) 0.037 (0.597) 0.031 (0.658) 0.002 (0.981) 0.032 (0.646) −0.034 (0.631)
Renal biopsy data
Activity index 0.188 (0.007) −0.215 (0.002) −0.007 (0.921) 0.072 (0.302) 0.053 (0.448)
The data are shown in correlation coefficient followed by p-value in parentheses. CONUT, Controlling nutritional
status; PNI, Prognostic nutritional index; NRI, Nutritional risk index; NLR, Neutrophil to lymphocyte ratio;
BMI, Body mass index; SLE, Systemic lupus erythematosus; SLEDAI-2K, Systemic lupus erythematosus disease
activity index-2000; WBC, White blood cell; P/Cr, Protein/creatinine; ESR, Erythrocyte sedimentation rate; CRP,
C-reactive protein; Cr, Creatinine; GFR, Glomerular filtration rate; CKD-EPI, Chronic kidney disease epidemiology
collaboration; AST, Aspartate aminotransferase; ALT, Alanine aminotransferase.
Concerning other variables, the lymphocyte count was significantly correlated with the CONUT
score, PNI, and NLR. The CRP was significantly correlated with the CONUT score, PNI, NLR, and BMI.
Creatinine levels only correlated with PNI, while GFR only correlated with BMI. The total cholesterol
level was correlated with the PNI, NLR, and BMI and the serum albumin level was found to be
correlated with the CONUT score, PNI, and NRI. Lastly, AST level was correlated only with the
CONUT score and the activity index seen on renal biopsy was correlated only with the CONUT score
and PNI (Table 2). On evaluating the associations with the nutritional indices, the CONUT score was
correlated with the PNI, NRI, and NLR (r = −0.780, r = −0.199, and r = 0.304, respectively). In addition,
the PNI was significantly correlated with NRI and NLR (r = 0.165, p = 0.018 and r = −0.272, p < 0.001)
and the NRI with BMI (r = 0.861, p < 0.001) (Supplementary Table S3).
3.3. Comparison of Different Nutritional Indices According to Lupus Nephritis Subclasses
Next, this study compared whether there was any difference in the nutritional indices included
based on LN subclasses. The patients with pure class IV LN had a significantly higher CONUT score
than patients with pure class III and V LN, as well as those with mixed class V LN. In addition, the PNI
was significantly lower in patients with pure class IV LN than in those with class II and pure class III
LN (Figure 1). Furthermore, patients with pure class III and class IV LN had a higher NLR than those
with pure class V nephritis. However, no significant difference was found regarding the NRI and BMI
according to LN classes (Figure 1). On the other hand, among the 5 nutritional indices included, only
PNI was capable of predicting ESRF (area under the ROC curve = 0.671, sensitivity 90.0%, specificity
46.0%, 95% confidence interval (CI) 0.602–0.734, p = 0.002), and the optimal cut-off of PNI in predicting
ESRF was determined to be PNI ≤35.41 (Figure 2).
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3.4. Factors Associated with End-stage Renal Failure in Patients with Lupus Nephritis
This study performed a Cox-proportional hazard analysis to elucidate the factors associated
with ESRF. In univariable analysis, the platelet and lymphocyte count, creatinine, GFR, chronicity
index, PNI, and NLR were significantly associated with ESRF. However, in multivariable analysis,
only creatinine (odds ratio (OR) 1.623, 95% CI 1.322–1.993, p < 0.001), chronicity index (OR 1.458,
95% CI 1.203–1.767, p < 0.001), and PNI (OR 0.925, 95% CI 0.865–0.989, p = 0.022) were independent
factors for ESRF (Table 3). The Kaplan-Meier analysis also revealed that patients with a low PNI had a
significantly higher probability of having ESRF than those with a high PNI (log rank test p = 0.003)
(Figure 3).Nutrients 2019, 11, x FOR PEER REVIEW 8 of 14 
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diagnosis. PNI, Prognostic nutritional index.
Table 3. The Cox-proportional hazard analysis of variables associated with end-stage renal failure
during the follow-up.
Univariable Analysis Multivariable Analysis
Variables Odds Ratio 95% ConfidenceInterval p-Value Odds Ratio
95% Confidence
Interval p-Value
SLEDAI-2K 0.904 0.803–1.016 0.091
WBC count (/mm3) 1.000 0.999–1.000 0.744
Platelet count (×1000/mm3) 0.993 0.987–0.999 0.015
Complement 3, mg/dL 0.992 0.974–1.010 0.362
Complement 4, mg/dL 0 995 0.938–1.054 0.853
Anti-dsDNA (IU/mL) 0.998 0.995–1.000 0.063
Urinary P/Cr ratio 1.078 0.964–1.206 0.185
Lymphocyte count (/mm3) 0.999 0.998–0.999 0.023
ESR (mm/h) 1.000 0.986–1.014 0.999
CRP (mg/L) 1.012 0.999–1.025 0.070
Cr (mg/dL) 1.827 1.522, 2.193 <0.001 1.623 1.322–1.993 <0.001
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Table 3. Cont.
Univariable Analysis Multivariable Analysis
Variables Odds Ratio 95% ConfidenceInterval p-Value Odds Ratio
95% Confidence
Interval p-Value
GFR (CKD-EPI),
mL/min/1.73 m2 0.959 0.944, 0.975 <0.001
Total cholesterol (mg/dL) 0.999 0.994–1.006 0.977
Serum albumin (g/dL) 0.569 0.311–1.041 0.067
AST (IU/L) 1.002 0.996–1.009 0.491
ALT (IU/L) 0.999 0.986–1.014 0.979
Pure proliferative lupus
nephritis¶ 4.300 0.998–18.534 0.050
Activity index 1.076 0.989–1.171 0.089
Chronicity index 1.493 1.254–1.778 <0.001 1.458 1.203–1.767 <0.001
CONUT score 1.230 0.957–1.582 0.106
PNI 0.932 0.880–0.987 0.017 0.925 0.865–0.989 0.022
NRI 1.007 0.959–1.057 0.789
NLR 1.070 1.020–1.122 0.006
BMI 1.029 0.908–1.167 0.651
¶Proliferative lupus nephritis was defined as either class III or IV lupus nephritis according to the International
Society of Nephrology/ Renal Pathology Society criteria. SLEDAI-2K, Systemic lupus erythematosus disease
activity index-2000; WBC, White blood cell; P/Cr, Protein/creatinine; ESR, Erythrocyte sedimentation rate; CRP,
C-reactive protein; Cr, Creatinine; GFR, Glomerular filtration rate; CKD-EPI, Chronic kidney disease epidemiology
collaboration; AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; CONUT, Controlling nutritional
status; PNI, Prognostic nutritional index; NRI, Nutritional risk index; NLR, Neutrophil to lymphocyte ratio; BMI,
Body mass index.
4. Discussion
To the best of the authors knowledge, the present study is the first to evaluate the clinical
significance of 5 different nutritional indices in patients with LN. Among the included indices,
the CONUT score and PNI were better correlated with SLE disease activity-related measures to assess
disease activity in LN. However, only the PNI was significantly lower in patients with ESRF at LN
diagnosis. On the Cox-proportional hazard analysis, the PNI was an independent predictor of ESRF
along with creatinine and chronicity index. Our observations imply that among the nutritional indices,
the CONUT score and PNI could be useful to assess disease activity. However, only PNI was seen to
have prognostic implications in identifying patients with LN at a high risk of developing ESRF.
The findings of our study indicate that the CONUT score and PNI could be useful markers to
assess both global and localized disease activity in patients with LN. Notably, the correlation analysis
between nutritional indices and SLE activity-related measures revealed that the CONUT score and
PNI were better correlated with the SLEDAI-2K, which is the most widely used index to assess global
SLE disease activity, along with WBC and platelet counts, C3, C4, and anti-dsDNA levels, urinary
P/Cr ratio (which is a laboratory component of the SLEDAI-2K), and the activity index as determined
through renal biopsy. Moreover, in patients with pure class IV LN, which is the most devastating
form of LN, the CONUT score and PNI were found to be significantly different compared to those of
other subclasses.
The CONUT score and PNI were first developed to estimate undernutrition and the risk
of postoperative complications in patients with gastrointestinal cancers, respectively. However,
accumulating evidences have identified that they are also associated with the prognosis of patients
with other malignancies and disorders related to malnourishment [25–28]. The association of the
CONUT score and PNI with SLE disease activity at LN diagnosis that was found in this study could be
explained by the fact that both indices are calculated using the lymphocyte count in the peripheral
blood and serum albumin level. Albumin is a negative acute phase protein that could decrease in
proportion to systemic inflammatory response and the hallmark of LN is proteinuria [29]. Therefore,
it is possible that both systemic and localized inflammation could contribute to the development of
hypoalbuminemia. Moreover, lymphopenia has been included as a hematologic criterion according
to the 1997 ACR and 2012 SLE International Collaborating Clinics SLE criteria [15,30] and has been
reported to be associated with SLE disease activity and prognosis [31]. Similar findings were found in
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previous studies in which PNI was significantly correlated with SLE disease activity independent of
other factors, supporting the results of our study [32,33].
Owing to the poor prognosis of LN, numerous attempts have been made to evaluate the prognostic
factors associated with LN. Regarding histopathological factors, the presence of proliferative LN
and higher activity and chronicity indices at diagnosis have been proposed to be associated with a
poor prognosis [34]. Contreras et al., and Singh et al., also demonstrated that higher creatinine and
chronicity index was a predictor of poor prognosis in LN [35,36]. Notably, our data revealed that
the PNI was an independent factor associated with ESRF in multivariate Cox-proportional hazard
analysis, along with creatinine and chronicity index in renal biopsy during the follow-up period.
Additionally, the renal survival rate in patients with low PNI was significantly lower than those with
high PNI, implying that PNI could provide additional information regarding the prediction of ESRF
in LN. However, the authors found that the presence of proliferative LN and activity index were not
significantly associated with ESRF, which could be associated with the disease-modulating effect of the
immunosuppressive agents administered.
Among nutritional indices included, our study indicated that only PNI was capable of assessing
renal outcome in patients with LN. Surprisingly, because the CONUT score had the highest correlation
with SLEDAI-2K and laboratory variables included in SLEDAI-2K at baseline, the association between
PNI and ESRF, instead of the CONUT score, was rather unexpected. However, the discordant results
between disease activity and the development of ESRF could be attributed to the fact that baseline
disease activity is not a predictive factor for patient prognosis in SLE [37]. In contrast, it has been
reported that persistent proteinuria, which could lead to hypoalbuminemia as a consequence of
albumin loss, as well as the serum albumin level itself, were indicative of renal outcomes in LN [38–40].
Compared to the CONUT score in which a relatively equal weighting is given between serum albumin,
lymphocyte count, and total cholesterol level, the PNI is mainly dependent on the serum albumin level.
Considering the importance of the serum albumin level in LN, it could be reasoned that the PNI could
serve as a more appropriate measure to assess renal outcomes than the CONUT score.
In the treatment of proliferative LN, current guidelines recommend treating patients with induction
therapy using either cyclophosphamide or mycophenolate mofetil, followed by sustained maintenance
therapy with mycophenolate mofetil or azathioprine [4]. When this study compared the treatment
between patients with ESRF and without, there were no significant differences in the proportion of
patients treated with glucocorticoids, cyclophosphamide, mycophenolate mofetil, and azathioprine,
suggesting that the selection of induction and maintenance treatment might not have substantially
affected the patients’ clinical outcomes.
BMI is the most widely used measure to assess obesity in the general population. A previous
study has indicated that the prevalence of obesity in patients with SLE was reported to range from
28–50% [41]. Similar findings were noted in our study population, as the proportion of overweight
patients (36.2%) was not significantly different. Interestingly, several reports have suggested that
obesity is associated with disease development and poor outcomes in patients with autoimmune
diseases. Previous studies have shown that obesity was associated with an increased risk of RA, SLE,
and psoriatic arthritis (PsA) [42–44]. In addition, it has been suggested that increased weight was
related to a lower possibility of sustained remission in patients with early RA and was related to higher
disease activity and diminished clinical response in patients with PsA [45,46]. Obesity has also been
suggested to be associated with an increased risk of cardiovascular disease in patients with SLE [47].
Although first recognized solely as a measure of body composition, obesity is now regarded as a mild
chronic inflammatory state that could affect the immune system via adipose-derived inflammation.
In addition, previous studies have suggested that high BMI is associated with increased proteinuria and
albuminuria [48]. Accordingly, a significant correlation was observed between BMI, CRP, and urinary
P/Cr ratio in the present study. However, in this study, BMI itself did not correlate with SLEDAI-2K and
the proportion of patients developing ESRF during the follow-up did not differ between the groups,
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implying that BMI may not be an appropriate measure to assess disease activity and the risk of ESRF
in LN.
The strength of this study is that, to the best of the authors’ knowledge, this is the first study
that evaluated the clinical significance of different nutritional indices in patients with LN. However,
several limitations were also present in our study. First, the assessment of clinical and laboratory data
was performed by reviewing patients’ medical records. Second, the number of patients with ESRF
included was relatively small. Third, serial changes in the nutritional indices were not assessable
and the adjustment for treatment was not possible owing to the retrospective study design. Fourth,
it remains uncertain if albumin replacement therapy could be beneficial in improving the prognosis in
patients with LN. Additional studies are required to validate our findings and reveal the association
between nutritional status and patient prognosis in LN.
5. Conclusions
In conclusion, the authors have demonstrated that among the nutritional indices examined in
this study, the CONUT score and PNI were better correlated with disease activity and the PNI was
associated with ESRF in patients with LN. Both the CONUT score and PNI could be useful measures
to assess disease activity; in particular, PNI may provide useful information in stratifying patients at
high risk of ESRF in LN.
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